{
    "title": "106_s3051",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Greater Access to Affordable \nPharmaceuticals Act'' or the ``GAAP Act of 2000''.\n\nSEC. 2. NEW DRUG APPLICATIONS.\n\n    (a) Limitations on the Use of Patents To Prevent Approval of \nAbbreviated New Drug Applications.--Section 505(b)(2) of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 355(b)(2)) is amended--\n            (1) in subparagraph (A)--\n                    (A) in the matter preceding clause (i), by striking \n                ``the drug for which such investigations were conducted \n                or which claims a use for such drug for which the \n                applicant is seeking approval under this subsection'' \n                and inserting ``an active ingredient of the drug for \n                which such investigations were conducted, alone or in \n                combination with another active ingredient or which \n                claims the first approved use for such drug for which \n                the applicant is seeking approval under this \n                subsection''; and\n                    (B) in clause (iv), by striking ``; and'' and \n                inserting a period;\n            (2) in the matter preceding subparagraph (A), by striking \n        ``shall also include--'' and all that follows through ``a \n        certification'' and inserting ``shall also include a \n        certification'';\n            (3) by striking subparagraph (B); and\n            (4) by redesignating clauses (i) through (iv) as \n        subparagraphs (A) through (D), respectively, and aligning the \n        margins of the subparagraphs with the margins of subparagraph \n        (A) of section 505(c)(1) of that Act (21 U.S.C. 355(c)(1)).\n    (b) Abbreviated New Drug Applications.--Section 505(j)(2)(A) of the \nFederal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(2)(A)) is \namended--\n            (1) in clause (vi), by striking the semicolon and inserting \n        ``; and''; and\n            (2) in clause (vii)--\n                    (A) in the matter preceding subclause (I), by \n                striking ``the listed drug referred to in clause (i) or \n                which claims a use for such listed drug for which the \n                applicant is seeking approval under this subsection'' \n                and inserting ``an active ingredient of the listed drug \n                referred to in clause (i), alone or in combination with \n                another active ingredient or which claims the first \n                approved use for such drug for which the applicant is \n                seeking approval under this subsection'';\n                    (B) in subclause (IV), by striking ``; and'' and \n                inserting a period; and\n                    (C) by striking clause (viii).\n    (c) Effective Date.--The amendments made by this section shall only \nbe effective with respect to a listed drug for which no certification \npursuant to section 505(j)(2)(A)(vii)(IV) of the Federal Food, Drug, \nCosmetic Act was made prior to the date of enactment of this Act.\n\nSEC. 3. CITIZEN PETITION REVIEW.\n\n    Section 505(j)(5) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 355(j)(5)) is amended--\n            (1) by redesignating subparagraphs (C) and (D) as \n        subparagraphs (D) and (E), respectively; and\n            (2) by inserting after subparagraph (B) the following:\n    ``(C) Notwithstanding any other provision of law, the submission of \na citizen's petition filed pursuant to section 10.30 of title 21, Code \nof Federal Regulations, with respect to an application submitted under \nparagraph (2)(A), shall not cause the Secretary to delay review and \napproval of such application, unless such petition demonstrates through \nsubstantial scientific proof that approval of such application would \npose a threat to public health and safety.''.\n\nSEC. 4. BIOEQUIVALENCE TESTING METHODS.\n\n    Section 505(j)(8)(B) of the Federal Food, Drug, and Cosmetic Act \n(21 U.S.C. 355(j)(8)(B)) is amended--\n            (1) in clause (i), by striking ``or'' at the end;\n            (2) in clause (ii), by striking the period and inserting \n        ``; or''; and\n            (3) by adding at the end the following:\n                    ``(iii) the effects of the drug and the listed drug \n                do not show a significant difference based on tests \n                (other than tests that assess rate and extent of \n                absorption), including comparative pharmacodynamic \n                studies, limited confirmation studies, or in vitro \n                methods, that demonstrate that no significant \n                differences in therapeutic effects of active or \n                inactive ingredients are expected.''.\n\nSEC. 5. ACCELERATED GENERIC DRUG COMPETITION.\n\n    (a) In General.--Section 505(j)(5) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355(j)(5)) is amended--\n            (1) in subparagraph (B)(iv), by striking subclause (II) and \n        inserting the following:\n                    ``(II) the date of a final decision of a court in \n                an action described in clause (ii) from which no appeal \n                can or has been taken, or the date of a settlement \n                order or consent decree signed by a Federal judge, that \n                enters a final judgement, and includes a finding that \n                the relevant patents that are the subject of the \n                certification involved are invalid or not infringed, \n                whichever is earlier,'';\n            (2) by redesignating subparagraphs (C) and (D) as \n        subparagraphs (D) and (E), respectively; and\n            (3) by inserting after subparagraph (B), the following:\n    ``(C) The one-hundred and eighty day period described in \nsubparagraph (B)(iv) shall become available to the next applicant \nsubmitting an application containing a certification described in \nparagraph (2)(A)(vii)(IV) if the previous applicant fails to commence \ncommercial marketing of its drug product once its application is made \neffective, withdraws its application, or amends the certification from \na certification under subclause (IV) to a certification under subclause \n(III) of such paragraph, either voluntarily or as a result of a \nsettlement or defeat in patent litigation.''.\n    (b) Effective Date.--The amendments made by this section shall only \nbe effective with respect to an application filed under section 505(j) \nof the Federal Food, Drug, Cosmetic Act for a listed drug for which no \ncertification pursuant to 505(j)(2)(A)(vii)(IV) of such Act was made \nprior to the date of enactment of this Act.\n\nSEC. 6. SENSE OF CONGRESS.\n\n    It is the sense of Congress that measures should be taken to \neffectuate the purpose of the Drug Price Competition and Patent Term \nRestoration Act of 1984 (referred to in this section as the ``Hatch-\nWaxman Act'') to make generic drugs more available and accessible, and \nthereby reduce health care costs, including measures that require \nmanufacturers of a drug for which an application is approved under \nsection 505(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n255(c)) desiring to extend a patent of such drug to utilize the patent \nextension procedure provided under the Hatch-Waxman Act.\n\nSEC. 7. CONFORMING AMENDMENTS.\n\n    (a) Applications.--Section 505 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355) is amended--\n            (1) in subsection (b)(3), in subparagraphs (A) and (C), by \n        striking ``paragraph (2)(A)(iv)'' and inserting ``paragraph \n        (2)'';\n            (2) in subsection (c)(3)--\n                    (A) in subparagraph (A), by striking ``clause (i) \n                or (ii) of subsection (b)(2)(A)'' and inserting \n                ``subparagraph (A) or (B) of subsection (b)(2)'';\n                    (B) in subparagraph (B), by striking ``clause (iii) \n                of subsection (b)(2)(A)'' and all that follows through \n                the period and inserting ``subparagraph (C) of \n                subsection (b)(2), the approval may be made effective \n                on the date certified under subparagraph (C).'';\n                    (C) in subparagraph (C), by striking ``clause (iv) \n                of subsection (b)(2)(A)'' and inserting ``subparagraph \n                (D) of subsection (b)(2)''; and\n                    (D) in subparagraph (D)(ii), by striking ``clause \n                (iv) of subsection (b)(2)(A)'' and inserting \n                ``subparagraph (D) of subsection (b)(2)''; and\n            (3) in subsection (j), in paragraph (2)(A), in the matter \n        following clause (vii)(IV), by striking ``clauses (i) through \n        (viii)'' and inserting ``clauses (i) through (vii)''.\n    (b) Pediatric Studies of Drugs.--Section 505A of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 355a) is amended--\n            (1) in subsection (a)(2)--\n                    (A) in clause (i) of subparagraph (A), by striking \n                ``(b)(2)(A)(ii)'' and inserting ``(b)(2)'';\n                    (B) in clause (ii) of subparagraph (A), by striking \n                ``(b)(2)(A)(iii)'' and inserting ``(b)(2)''; and\n                    (C) in subparagraph (B), by striking ``subsection \n                (b)(2)(A)(iv)'' and inserting ``subsection (b)(2)''; \n                and\n            (2) in subsection (c)(2)--\n                    (A) in clause (i) of subparagraph (A), by striking \n                ``(b)(2)(A)(ii)'' and inserting ``(b)(2)'';\n                    (B) in clause (ii) of subparagraph (A), by striking \n                ``(b)(2)(A)(iii)'' and inserting ``(b)(2)''; and\n                    (C) in subparagraph (B), by striking ``subsection \n                (b)(2)(A)(iv)'' and inserting ``subsection (b)(2)''.\n    (c) Definition.--Section 201 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 321) is amended by adding at the end the \nfollowing:\n    ``(kk) For purposes of the references to court decisions in clauses \n(i) and (iii) of section 505(c)(3)(C) and clauses (iii)(I), (iii)(III) \nof section 505(j)(5)(B), the term `the court' means the court that \nenters final judgment from which no appeal (not including a writ of \ncertiorari) can or has been taken.''."
}